Valgen Medtech

Hangzhou Valgen Medtech Co., Ltd. (hereinafter referred to as "Valgen Medtech") focuses on the field of interventional treatment for structural heart disease. Established in Hangzhou in 2015, by the end of 2023, the company has applied for over 500 patents globally, with more than 150 already authorized. Three innovative products independently developed by the company have passed the special review process for innovative medical devices by the drug regulatory authority. The company's multiple interventional treatment devices, represented by the Dragon series, will greatly enrich clinical options in China for the treatment of structural heart disease. Among them, the DragonFly™ Transcatheter Mitral Valve Clip System, as the first China-developed transvenous edge-to-edge repair product in the country, passed the special review process for innovative medical devices by the drug regulatory authority in March 2021 and was officially approved by NMPA for marketing in China on November 29, 2023. This product received support from the Ministry of Science and Technology's "14th Five-Year Plan" National Key Research and Development Program. In addition, currently marketed products include Sister Pu™ Medical Radiation Protection Screen, Magpie™ Balloon Dilation Catheter, DragonPath™ Atrial Septal Puncture System, Firework™ Rigid Guidewire Series, and other products. The company's headquarters is located in Hangzhou National High-tech Industrial Development Zone (Binjiang District), with an innovation research and development center in Shenzhen. The enterprise has successively been recognized as a national and Zhejiang provincial technology-based small and medium-sized enterprise, Hangzhou High-tech Research and Development Center, and Hangzhou Engineering Research Center. In the future, Valgen Medtech will adhere to the corporate development strategy of "rooted in China, facing the world," accelerate the incubation of more self-developed devices that address domestic clinical pain points, spare no effort in promoting clinical applications, and provide better treatment solutions for patients in China and even globally.